Pure Global AI
NCT06267690Completed

A CT-based Radiomics Model to Predict Survival-graded Fibrosis in PDAC

Development and Validation of a CT-based Radiomics Model to Predict Survival-graded Fibrosis in Pancreatic Ductal Adenocarcinoma
First Affiliated Hospital, Sun Yat-Sen UniversityClinicalTrials.govprocedure
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
surgery
Study type
Observational
Intervention type
procedure
Sponsor & location
Primary sponsor
First Affiliated Hospital, Sun Yat-Sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
N/A
Start date
Jan 13, 2021
End date
Aug 31, 2023
Enrollment
295 participants
Primary outcome

fibrosis

Summary

Tumor fibrosis plays an important role in chemotherapy resistance in pancreatic ductal
 adenocarcinoma (PDAC), however there remains a contradiction in the prognostic value of
 fibrosis. We aimed to investigate the relationship between tumor fibrosis and survival in
 patients with PDAC, classify patients into high- and low-fibrosis groups, and develop and
 validate a CT-based radiomics model to non-invasively predict fibrosis before treatment.

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06267690
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06267690 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital, Sun Yat-Sen University and is currently Completed. The study focuses on Pancreatic Cancer. Target enrollment is 295 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.